Home » Stocks » Verona Pharma

Verona Pharma PLC (VRNA)

Stock Price: $6.01 USD 0.18 (3.09%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 311.43M
Revenue (ttm) n/a
Net Income (ttm) -31.94M
Shares Out 51.82M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $6.01
Previous Close $5.83
Change ($) 0.18
Change (%) 3.09%
Day's Open 5.82
Day's Range 5.82 - 6.39
Day's Volume 236,508
52-Week Range 2.01 - 15.71

More Stats

Market Cap 311.43M
Enterprise Value 281.62M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 51.82M
Float 40.43M
EPS (basic) -30.30
EPS (diluted) -2.34
FCF / Share -0.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 145,239
Short Ratio 1.04
Short % of Float 0.36%
Beta -0.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.56
Revenue n/a
Operating Income -41.08M
Net Income -31.94M
Free Cash Flow -38.22M
Net Cash 29.81M
Net Cash / Share 0.58
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.08%
ROE -99.94%
ROIC -148.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(214.31% upside)
Current: $6.01
Target: 18.89
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-41.08-25.59-29.76-7.02-8.98
Net Income-31.94-19.90-20.50-5.02-7.50
Shares Outstanding105105103103-
Earnings Per Share-30.30-18.90-23.40-15.00-37.10
Operating Cash Flow-38.18-22.70-21.51-7.12-7.06
Capital Expenditures-0.04-0.01-0.01-0.01-
Free Cash Flow-38.22-22.71-21.52-7.13-7.06
Cash & Equivalents30.7664.7080.2639.793.52
Total Debt0.95----
Net Cash / Debt29.8164.7080.2639.793.52
Book Value33.8763.4279.8834.475.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Verona Pharma PLC
Country United Kingdom
Employees 33
CEO David S. Zaccardelli

Stock Information

Ticker Symbol VRNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VRNA
IPO Date April 27, 2017


Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.